Tumor samples were obtained from 30 patients with pathogenic germline variants in BRCA2 (n = 25) and BRCA1 (n = 5), as well as from an additional 30 patients without pathogenic germline mutations. This evidence concerns the gene BRCA1 and neoplasm.